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ABSTRACT 
 
The development of novel drugs that have chemotherapeutic activity against cancer is a 
great challenge. The discoveries of these drugs are very difficult, because they must be 
able to destroy the tumor cells without causing adverse side effects. Significant 
innovations come forth when human cell lines are used for vetting drugs and other 
chemicals. Embelin, a benzoquinone is reported to possess anticancer activity on 
various cancer cell lines. The present investigation was undertaken to determine the 
toxicity profile of embelin on human peripheral blood lymphocytes and murine 
macrophages. The effect of embelin on growth and viability of cells was determined by 
MTT assay. Further embelin was tested for mutagenicity by the Ames test, in 
Salmonella typhimurium strains with and without metabolic activation.  Results implicate 
that embelin was non mutagenic in the tester strains used in the study and did not 
adversely influence the proliferation of lymphocytes and macrophages and the IC50 was 
found to be 78.7µg/ml and 128.54µg/ml respectively. 
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INTRODUCTION 
 
Embelin, a benzoquinone and XIAP inhibitor is 
known to possess anticancer activity against the 
various cell lines. Embelin exhibits antifertility, 
antitumor, anti-inflammatory, analgesic, 
antioxidant, hepatoprotective, wound healing 
and antibacterial1, 2, 3 activities. It also possess a 
wide spectrum of biological activities with a 
strong inhibition of NF-KB and down regulation 
of variety of gene products involved in tumour 
cell survival, proliferation, invasion, 
angiogenesis and inflammation4. The chemical 
structure of embelin has resemblance with that 
of natural coenzyme Q10 (ubiquinones) and the 
role of this is well defined in various biochemical 
protective mechanisms5. It is a potent, 
nonpeptidic molecule because of the presence 
of both quinone and phenolic groups on the 
same ring. Recently, several phenolic 
compounds have demonstrated antimutagenic 
effect on various mutagens or carcinogens6. It 
has been shown that a procedure called the 
Ames test is a safe way to assess mutagenicity 
of various agents. The Ames test is used 
worldwide as an initial screen to determine the 
mutagenic potential of new chemicals and 
drugs. The test is also used for submission of 
data to regulatory agencies for registration or 
acceptance of many chemicals, including drugs 
and biocides. The Ames Salmonella/microsome 
mutagenicity assay (Salmonella test; Ames test) 
is a short-term bacterial reverse mutation assay, 
specifically designed to detect a wide range of 
chemical substances that can produce genetic 
damage and leads to gene mutations. The test 
employs several histidine 
dependent Salmonella strains, each carrying 
different mutations in various genes in the 
histidine operon. These mutations act as hot 
spots for mutagens that cause DNA damage via 
different mechanisms. When 
the Salmonella tester strains are grown on a 
minimal media agar plate containing a trace of 
histidine, only those bacteria that revert to 
histidine independence are able to form 
colonies. The number of spontaneously induced 
revertant colonies per plate is relatively 
constant. However, when a mutagenic agent is 
added to the plate, the number of revertant 
colonies per plate increases, usually in a dose-
related manner7. In this study, mutagenic effect 
of embelin was assessed using the Ames 
assay. Further, the antitumor activity of the drug 
is generally based on the mechanism of action 
as to how these agents are effective in killing 
the tumor cells or in preventing the growth of 
the tumor cells. Tumor cells unlike the normal 
cells fail to respond to homeostatic control 
mechanism and there by continuous cell 
proliferation occurs8, 9. The kinetic techniques 
help us determine the tumor growth in relation 
to normal cell growth10. It is commonly seen that 
most of the anticancer drugs used produce non 
selective cell killing of normal as well as 
cancerous tissues and they act more against 
tumor than normal cells. Chemotherapeutic 
drugs kill healthy cells as they pass through the 
body on their way to the cancerous target. Also, 
they have adverse side effects and sometimes 
end up being ineffective of resistant. This may 
be due to the quantity or dosage of these drugs 
circulating in the body. It may be true that the 
effect of chemotherapeutic agents on tumor 
cells can be more than ten thousand times 
greater than the normal cells11. Normal cell 
systems can theoretically withstand greater 
cellular losses to chemotherapy than can tumor 
cells12. Therefore research needs to be done in 
search for the drugs that can exploit the unique 
biochemical difference between normal and 
cancerous cells. Henceforth in the study, 
embelin is used to check for the selective 
cytotoxic effects using the normal human 
peripheral blood lymphocytes and 
macrophages. Using human peripheral blood 
lymphocytes as an alternative source of 
hematopoietic cells is methodological simple 
and straight forward. It could possibly be used 
to complement the progenitor models, and 
serve as a model for a differentiated and 
nonproliferating peripheral blood cell. So here in 
the study, we attempt to make a toxicity profiling 
with normal cells. The test not only determines 
the toxicity, but also the dosage levels at which 
these can produce the toxicity. All anticancer 
drugs are highly cytotoxic agents and may be 
toxic to normal cells especially the rapidly 
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dividing bone marrow cells, fetal cells, germ 
cells etc. In order to evaluate the cytotoxic 
effects of embelin   MTT assay was performed 
on both lymphocytes and macrophages in vitro. 
 
MATERIALS AND METHODS 
 
i. Preparation of stock solution of embelin 
Embelin was procured from Sigma-Aldrich Co. 
(St. Louis, MO, USA). It was solubilised in 
DMSO (final concentration of DMSO is 0.1%) 
and various aliquots from stock solutions were 
used throughout the assays indicated. 
 
ii.Test to confirm the non-mutagenic  effects 
of embelin- Ames test 13 
The non-mutagenic property of embelin was not 
reported previously. As embelin exhibits potent 
anticancer activity, it becomes further necessary 
to check the anti-mutagenic effects of embelin. 
This test was performed using standard plate 
incorporation procedures as 
escribedpreviously13. The test was carried in the 
presence and absence of liver S9 mix. Two 
histidine deficient (his-) tester strains of 
Salmonella typhimurium namely TA-98 and TA-
100 were procured from Microbial Type Culture 
Collection, MTCC, Chandigarh- India and were 
used to detect the frame shift and base pair 
substitution mutagens respectively. Prior to the 
use in the assay, strains were checked for the 
presence of strain specific markers. The S9 
fraction of the liver was prepared following 
standard methods reported earlier 12. The 
fraction was aliquoted in 1-2ml portions and 
stored at -80 C. The S9 mix was freshly 
prepared with 8mM MgCl2, 33mM KCl, 5mM 
Glucose 6 Phosphate, 4mM NADP, 100mM 
Sodium Phosphate and the S9 fraction at a 
concentration of 0.1ml/ml of mix. For the test, 
Embelin was used at concentration of 25 µg, 50 
µg and 100 µg per plate. NPD, 4-nitro-o-
phenylenediamine (200µg/plate) and SA, 
Sodium Azide (1µg/plate) were used as positive 
mutagens for TA-98 and TA-100, respectively. 
In the presence of S9 mix, 2-AF, 2-Amino 
fluorine (20µg/plate) was used as a positive 
mutagen for both the strains as it required a 
metabolic activator. The number of revertants 
was counted and tabulated. 
iii. Blood Withdrawal 
Fresh human peripheral blood was drawn by 
venipuncture from healthy volunteers aging 
between 18-20 sticking on to the regulations 
laid down by the Helsinki protocol. Post 
collection, the blood was aseptically transferred 
to sterile disposable centrifuge tubes containing 
EDTA. This  was used for the isolation of 
lymphocytes within two hours of collection. 
 
iv. Isolation and culture of lymphocytes  
Lymphocytes were separated from the freshly 
collected blood following the protocol described 
previously14. Lymphocyte separation of whole 
blood was based on density gradient 
centrifugation using Separation media (HiSep 
TM-LSM 1001) procured from Himedia 
Laboratories Private Ltd, Mumbai, India. 
Lymphocytes having >90% of viability (as 
ascertained by trypan blue staining) were 
suspended in 1ml of complete DMEM 
containing 10% FBS. Cell count was adjusted to 
5×106 cells /ml and cells were plated onto 96 
well microtiter plates and incubated at 37˚C with 
5% CO2 and 95% humidity in a CO2 incubator 
(Forma Scientific, USA). 
 
v. Procurement of Mouse macrophage cell 
line RAW 264.7 and culture 
The murine macrophage cell line RAW 264.7 
was procured from National Center for Cell 
Science, Pune, India. The cells were maintained 
in DMEM medium supplemented with 10% Fetal 
Bovine Serum and antibiotic/antimycotic 
solution. On confluency, the cells were 
detached with Trypsin- EDTA and subcultured 
in 25cm2 tissue culture flasks at a split ratio of 1: 
3 and for further arriving at confluency were 
plated onto 96 well microtiter plates for the 
assays or cryopreserved in appropriate medium 
in liquid nitrogen for further use. 
 
vi. MTT assay 15 
This was performed following the method 
described previously15. The assay was 
optimized for the experiment. Briefly, 5×106 cells 
per well was cultured in 96 well plate overnight 
and pretreated with various concentrations of 
Embelin and allowed to proliferate for 72 hours. 
After 72 hours of proliferation 25 µl of MTT 
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(10mg/ml in PBS) was added to the wells and 
plates were incubated for 5 to 6 hours and the 
formazan crystals formed were solubilised by 
adding 75 µl of DMSO and the plate was read at 
570nm.The concentrations that inhibited cell 
growth by 50% (IC50) after 72hours of treatment 
were calculated based on the survival rate 
compared with the untreated cells. 
 
vii. Data Analysis and Statistical methods 
In vitro experiments were carried out using 
three cultures, each time for each treatment and 
then repeated twice. Results were given as 
means of SD. Statistical differences were 
assessed by Student’s t-test, comparisons were 
made with untreated control and embelin 
treated cells and values were expressed as 
follows ***P< 0.001; **P< 0.01;* P< 0.05. 
 
 
 
 
RESULTS AND DISCUSSION 
 
It is essential to evaluate the biohazard nature of 
chemicals having potential as chemotherapeutic 
agents in order to work out the risk-benefit 
situation for the use of these compounds. The 
S.typhimurium mutagenicity system provides an 
efficient pre-screen to detect potentially 
hazardous chemicals16. The standard plate 
incorporation methods for the Ames test using 
Salmonella typhimurium standard tester strains 
TA-98 and TA-100 exposed to embelin with and 
without S9 metabolic activation were performed. 
The Ames test without S9 metabolic activation 
can only detect direct mutagens while with S9 
metabolic activation allows the detection of 
indirect mutagens, often caused by conjugation 
reactions of metabolic oxidation systems. Table 
1 present the reversion response of the 
Salmonella typhimurium tester strain to the 
different dilutions of the embelin (100 µg/plate, 
50 µg/plate, 25 µg/plate). 
 
Table 1 
Mutagenic effects of Embelin on S.typhimurium TA-98 and TA-100 strains 
 
Test Substances Concentration 
(µg/plate) 
TA-98 TA-100 
-S9 +S9 -S9 +S9 
NPD 200 µg/plate 5300±371*** _ _ _ 
2-AF 20 µg/plate _ 4774±334.18
* 
_ 1326±92.82*
* 
SA 1 µg/plate _ _ 432±29.37* _ 
Spontaneous 
control 
_ 9±0.63 33±2.24 146±9.92 79±5.53 
Embelin (100µg) 100 µg/plate 17±1.19* 16±1.08*** 54±3.67* 49±3.43* 
Embelin (50 µg) 50 µg/plate 22±1.54* 16±1.11* 15±1.08* 52±3.64* 
Embelin (25 µg) 25 µg/plate 22±1.50* 12±0.84* 44±3.08* 75±5.25* 
DMSO (1%) 200 µl/plate 41±2.87* 12±0.97 73±5.12** 71±4.97* 
                   Values are expressed as mean ±SD, Students ‘t’ test - Comparisons are made with the control 
                   P< 0.001; **P< 0.01; P< 0.05; NS: Non significant. 
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Figure 1 
Revertant colonies as observed in AMES test 
 
 
 
The results revealed that embelin was non-
mutagenic towards the Salmonella typhimurium 
strains used for the assay with and without 
metabolic activation. The average His+ 
revertants observed for all the tester strains 
caused by the embelin at all the concentrations 
with and without metabolic activation did not 
satisfy the criteria for mutagenicity. There was 
no notable dose-dependent increase in the 
number of revertants (Fig.1) and the numbers of 
revertants were all either not equal to or greater 
than twice that of the negative control. There 
was also no decrease in the number of 
revertant colonies to levels far below the 
negative control (spontaneous reversion) which 
could also be classified as toxic. Results of the 
MTT assay indicate that the lymphocytes 
treated with embelin (10 µg/ml to 100 µg/ml) did 
not show any significant decrease in 
proliferation at low doses but showed a marked 
decrease in proliferation at high doses (Fig.2) 
as compared to control. The decrease in 
proliferation observed at high doses was found 
to be statistically significant (P<0.001). IC50 
value of embelin were found to be 78.7µg/ml on 
human peripheral blood lymphocytes. Further 
the effect of embelin on the proliferation of 
macrophages was determined and IC50 value 
was found to be 128.54µg/ml (Fig.3). 
 
Figure 2 
Effect of embelin on proliferation of human peripheral blood lymphocytes 
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Figure 3 
Effect of embelin on proliferation of murine macrophages 
 
 
 
CONCLUSION 
 
We report for the first time, the non-mutagenic 
potential of benzoquinone and apoptosis 
activator embelin on Salmonella typhimurium 
tester strains TA-98 and TA-100.  The results 
also indicate that the IC50 values of embelin are 
quite high on lymphocytes and macrophages 
implicating its less toxic effects on normal cells 
as against cancer cells. This could be because 
of the fact that embelin has affinity for cancer 
cells that express more levels of XIAP (X-
linked inhibitor for apoptosis) than the normal 
cells. The high IC50 in normal cells also justifies 
the traditional use of Embelia ribes (the plant 
which is a rich source of embelin) which was 
perceived both as food and medicine in ancient 
Indian systems of medicine. The results 
indicate the potential use of embelin against 
cancer and oxidative stress-related diseases.  
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